Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants
Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC reported beneficial ownership of 3,458,327 Tenax Therapeutics (TENX) securities, including 2,500,000 common shares and pre-funded warrants for 958,327 additional shares. Based on 37,423,917 shares outstanding as of July 28, 2026 plus warrant shares, the stake equals 9.0%. They report sole voting and dispositive power.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on signals such as additional filings (13D/13G amendments), board or governance actions, or warrant exercise/dilution expectations, but this text alone does not confirm those catalysts.
Market read
A new beneficial-ownership disclosure establishes a 9% stake with sole voting and dispositive power, which can influence control expectations but lacks new operating catalysts.
What to watch
Pre-funded warrants’ exercise price and expiration terms are not provided here, which limits the ability to gauge dilution risk or near-term cash inflow.
Background
The filing summary describes a significant shareholder group led by Vivo Opportunity entities and their beneficial ownership of Tenax securities, including pre-funded warrants.
Ticker impact
Vivo Opportunity Fund Holdings and its GP report beneficial ownership of 9.0% of Tenax Therapeutics, including 2.5M shares plus pre-funded warrants.
Likely limited near-term impact; any move would be sentiment-driven around ownership/control optics rather than new company fundamentals.
The article provides a new beneficial-ownership percentage and warrant structure, but no new clinical, regulatory, financial, or deal information for Tenax.
Market effects
Minimal, as the disclosure is company-specific and does not describe sector-wide regulatory or clinical developments.
None indicated.
None indicated.
Counterpoint
A 9% holder can be passive or part of a prior financing structure; without evidence of activism or new funding terms, the market may overreact.
Key entities
- issuerTenax Therapeutics, Inc.
Company subject of the ownership disclosure, with 9.0% beneficial ownership reported by Vivo Opportunity entities.
- shareholderVivo Opportunity Fund Holdings, L.P.
Reporting person holding 2,500,000 common shares plus pre-funded warrants.
- shareholderVivo Opportunity, LLC
General partner and part of the reporting persons with sole voting and dispositive power.
